Ixekizumab improved function, other parameters in treatment of PsA

15:10 EDT 15 Jun 2017 | Healio

MADRID — Improvements in arthritis outcomes, physical function and psoriasis were reported for treatment with ixekizumab among patients with active psoriatic arthritis, according to findings presented at the EULAR Annual Congress.Peter Nash, MD, a rheumatologist at the University of Queensland in Brisbane, Australia, conducted the 24-week, double-blind, placebo-controlled phase 3 study in a cohort of 336 patients with inadequate response or intolerance to prior therapy. Overall, 118 patients received placebo; 122 patients were treated with 80 mg ixekizumab (Eli Lilly) every 4 weeks; and 123 patients received that dose of the study drug every 2 weeks. Patients in the ixekizumab arms received a 160-mg starting dose.

Original Article: Ixekizumab improved function, other parameters in treatment of PsA


More From BioPortfolio on "Ixekizumab improved function, other parameters in treatment of PsA"

Quick Search


Relevant Topics

According to the National Arthritis Data Workgroup, an estimated 6 million people in the United States report having experienced gout at some point in their lives. In fact, gout is the most common form of inflammatory arthritis in men over the age of 40....

Psoriasis is a common skin condition affecting 2-3% of the population of the United Kingdom, where the skins replacement process is sped taking 2-6 days instead of the usual 21 - 28 days for the replacement of skin cells. Patients experience an accumulat...

Joint Disorders
A joint is where two or more bones come together, like the knee, hip, elbow, or shoulder. Joints can be damaged by many types of injuries or diseases, including Arthritis - inflammation of a joint causes pain, stiffness, and swelling with ...